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Abstract
Autism spectrum disorders (ASD) are a group of pervasive neurodevelopmental disorders diagnosed in early child-
hood. They are associated with a set of “core symptoms” that include disabilities in social interaction skills, verbal
and non-verbal communication, as well as repetitive and stereotypic behaviors. There is no definite pathogenetic
mechanism or diagnostic tests. Many children with ASD also have “allergic-like” symptoms, but test negative imply-
ing mast cell activation by non-allergic triggers. We measured by Milliplex arrays serum levels of 3 neuropeptides
that could stimulate mast cells in children with autistic disorder (n = 19; 16 males and 3 females; mean age 3.0 ±
0.4 years) and healthy, unrelated controls (n = 16; 13 males and 3 females; mean age 3 ± 1.2 years). Only neuro-
tensin (NT) was significantly increased from 60.5 ± 6.0 pg/ml in controls to 105.6 ± 12.4 pg/ml in autistic disorder
(p = 0.004). There was no statistically significant difference in the serum levels of b-endorphin or substance P (SP).
NT could stimulate immune cells, especially mast cells, and/or have direct effects on brain inflammation and ASD.
Background
Autism spectrum disorders (ASD) are a group of neuro-
developmental disorders that include autistic disorder,
Asperger’s disorder, and pervasive developmental disor-
der-not otherwise specified (PDD-NOS) [1,2]. These are
diagnosed in early childhood and are characterized by a
set of “core symptoms” that include various degrees of
disability in social interaction skills, verbal and non-ver-
bal communication, as well as limited interest in activ-
ities often associated with repetitive and stereotypic
behaviors [1,2]. The diagnosis of ASD has increased dur-
ing the last decade to about 1/100 children [3,4]. How-
ever, there is neither distinct pathogenesis, nor reliable
biomarkers [5].
A number of papers have suggested that ASD may be
associated with some immune dysfunction in the patient
[6] or the mother during gestation [7]. More recently,
evidence has been reviewed suggesting that ASD may
have a neuroimmune component involving non-allergic
activation of mast cells by triggers such as neuropeptides
[8]. However, few studies have measured levels of neuro-
peptides in autism. Most of the investigations have
focused on oxytocin and vasopressin [9].
In one paper, archived neonatal blood was analyzed
with immunoaffinity chromatography and serum levels of
vasoactive intestinal peptide (VIP) and calcitonin-gene
related peptide (CGRP) were higher in children with
ASD (n = 69) and those with mental retardation without
ASD (n = 60); in contrast, levels of substance P (SP) and
nerve growth factor (NGF) were similar to those of con-
trols [10]. However, a subsequent study by the same
author using Luminex immunoaffinity arrays showed no
difference in any of these molecules between autistic sub-
jects and controls [11]. Another study showed signifi-
cantly elevated levels of b-endorphin in the cerebrospinal
fluid (CSF) of children with infantile autism (n = 9), but
serum levels were not measured [12].
We investigated serum levels of b-endorphin, neuroten-
sin (NT) and SP, all of which are present both in the
brain and the gut and are known mast cell triggers [13].
Here we report that NT is the only neuropeptide signifi-
cantly elevated in the serum of children with autistic dis-
order as compared to unrelated age-matched, normally
developing, control children.
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Study population
Patients came from the Second Department of Psychia-
try at Attikon General Hospital, University of Athens
Medical School (Athens, Greece), an NIH-approved site
for biological samples under a collaboration agreement
between Athens and Tufts Universities.
Patient assessment
All children were assessed by trained ASD clinicians.
Parents signed an appropriate consent form according
to the Helsinki principles. The ADI-R and ADOS-G
scales were used as they have also been validated in the
Greek population [14]. The Childhood Autism Rating
Scale (CARS) was completed as a further measurement
of the severity of ASD. A test for Fragile × syndrome
was ordered and the subjects were screened with
Wood’s Lamp for tuberous sclerosis.
The inclusion and exclusion criteria for the study were
as follows:
Inclusion criteria
1. Must meet ICD-10 criteria for autistic disorder.
Exclusion criteria
1. Any medical condition likely to be etiological for
ASD (e.g. Rett syndrome, focal epilepsy).
2. Any neurologic disorder involving pathology
above the brain stem, other than uncomplicated
non-focal epilepsy.
3. Contemporaneous evidence, or unequivocal retro-
spective evidence, of probable neonatal brain
damage.
4. Any genetic syndrome involving the CNS, even if
the link with autism is uncertain.
5. Clinically significant visual or auditory impair-
ment, even after correction.
6. Any circumstances that might possibly account
for the picture of autism (e.g. severe nutritional or
psychological deprivation).
7. Active treatment with pharmacological or other
agents.
8. Mastocytosis (including urticaria pigmentosa).
9. History of upper airway diseases.
10. History of inflammatory diseases.
11. History of allergies.
There were no other apparent clinical differences (e.g.
gastrointestinal problems) that may have allowed separa-
tion of the autistic patients in subgroups. The ASD sam-
ple consisted of 19 children with autistic disorder. The
controls were normally developing, healthy children,
unrelated to the autistic subjects, without any of the
exclusion criteria (n = 16; 13 males and 3 females; mean
age 3 years); these subjects were seen for routine health
visits at the Pediatric Department of the Institute of
Social Health Insurance, Greece. There were no identi-
fiers except for age and sex.
Objective measurements
Blood was obtained in the morning at least 2 hours after
breakfast to minimize any diurnal or postprandial
effects. Serum from patients and controls was aliquoted
and frozen at -80°C until assayed. All samples were
labeled only with a code number, as well as the age and
sex of the respective subject. Samples were analyzed for
neuropeptides and cytokines using Milliplex MAP,
based on the Luminex xMAP technology by Millipore
(Billerica, MA).
Statistical analysis
The results for serum neuropeptide levels are presented
as scattergrams, with the horizontal lines indicating the
means, in order to appreciate the distribution of the
values. The ASD group was compared to the controls
using unpaired, unequal, 2-tailed, Student’s t-test, as
well as the non-parametric Mann-Whitney U test. Sig-
nificance of comparisons between healthy subjects and
subjects with ASD is denoted by p < 0.05.
Results
The ASD group consisted of 19 patients (16 males and 3
females; mean age: 3.0 ± 0.4 years; range: 2.5-3.5 years)
all with a diagnosis of autistic disorder. The control
group consisted of 16 subjects (13 males and 3 females;
mean age: 3 ± 1.2 years; range: 2-5.5 years). These were
healthy, normally developing subjects, unrelated to the
ASD patients.
Serum was analyzed for the neuropeptides b-endor-
phin, NT and SP. Only NT was significantly elevated
(Figure 1) compared to controls (p = 0.004). Specifically,
the serum NT level in the subjects with autistic disorder
was 105.6 ± 12.4 pg/ml, as compared to 60.5 ± 6.0 pg/
ml in the controls. There was no statistical difference in
the serum levels of b-endorphin in autistic subjects
(328.0 ± 19.7 pg/ml) compared to the controls (312.8 ±
15.3 pg/ml) (Figure 2). Serum levels of SP did not differ
between the 2 groups either (16.1 ± 0.5 in ASD com-
pared to 16.0 ± 0.7 in the controls) (Figure 3).
We also investigated serum levels of cytokines usually
associated with mast cells (IL-4, IL-6, IL-10, IL-13,
TNF), but there was no statistically significant difference
(results not shown).
Discussion
Our present results indicatet h a tN Ti se l e v a t e di nt h e
serum of young children with autistic disorder, as com-
pared to unrelated, normally developing controls. All
Angelidou et al. Journal of Neuroinflammation 2010, 7:48
http://www.jneuroinflammation.com/content/7/1/48
Page 2 of 5subjects were selected to exclude any allergic, inflamma-
tory or neurologic diseases in order to avoid any con-
founding factors. The distribution of NT values in the
ASD subjects suggests there may be two subgroups.
However, nothing in the history or physical examination
allowed such subdivision. SP was not elevated as also
previously reported [10,11]; b-endorphin was also not
elevated, even though it had been reported to be
increased in the CSF of a small group of children
(n = 9) with infantile autism [12].
This is the first study to report measurements of NT
in the serum of human subjects with Luminex
microbead arrays. No physiological levels of NT have
been established for any disease state yet. However, one
study reported plasma NT levels measured by RIA in
healthy neonates to be 59.1 ± 23.9 pg/ml [15]. Another
study evaluated the role of NT in growth regulation in
subjects of different ages and reported that plasma levels
gradually declined with increasing age with plasma levels
in prepubertal children being 22.2 ± 4.8 pg/ml [16].
NT is a peptide originally isolated from the brain
[17]. It is present also in the gastrointestinal tract,
where it can induce intestinal inflammation [18]. NT
can stimulate lymphocyte proliferation [19], activate T
cells [20], and enhance IL-1 production from macro-
phages [21]. NT is also a potent trigger of mast cells
[22]. These effects are relevant to the findings that
many children with ASD also present with gastroin-
testinal and “allergic-like” symptoms [23]. In particular,
mast cells appear to be activated in ASD as suggested
by more food allergies [24] and increased atopic symp-
toms in Asperger patients [25]. Such “allergic symp-
toms” often occur in the absence of elevated serum
IgE or positive skin prick tests [26], suggesting mast
cell activation by non-immune triggers [13]. Moreover,
a preliminary report indicated that ASD is 10-times
more frequent in mastocytosis patients (1/10 children)
[27] than the general population (1/100 children) [4].
Mastocytosis is a rare disorder, which presents with
skin reactions, food allergies or food intolerance, diar-
rhea, anxiety [28], but also lack of concentration
("brain fog”), and hyperactivity [29].
Figure 1 Serum levels of neurotensin in ASD patients (n = 19;
16 males and 3 females; mean age: 3 ± 0.4 years; range: 2.5-
3.5 years) and controls (n = 16; 13 males and 3 females; mean
age: 3 ± 1.2 years; range: 2-5.5 years). Serum was analyzed using
Milliplex MAP, based on the Luminex xMAP technology by Millipore.
The horizontal lines indicate the means.
Figure 2 Serum levels of b-endorphin in ASD patients (n = 19;
16 males and 3 females; mean age: 3 ± 0.4 years; range: 2.5-
3.5 years) and controls (n = 16; 13 males and 3 females; mean
age: 3 ± 1.2 years; range: 2-5.5 years). Serum was analyzed using
Milliplex MAP, based on the Luminex xMAP technology by Millipore.
The horizontal lines indicate the means.
Figure 3 Serum levels of substance P in ASD patients (n = 19;
16 males and 3 females; mean age: 3 ± 0.4 years; range: 2.5-
3.5 years) and controls (n = 16; 13 males and 3 females; mean
age: 3 ± 1.2 years; range: 2-5.5 years). Serum was analyzed using
Milliplex MAP, based on the Luminex xMAP technology by Millipore.
The horizontal lines indicate the means.
Angelidou et al. Journal of Neuroinflammation 2010, 7:48
http://www.jneuroinflammation.com/content/7/1/48
Page 3 of 5NT could be released from the brain, the intestines
or dorsal root ganglia and could act together with
environmental triggers such as mercury [30] or corti-
cotropin-releasing hormone (CRH), secreted under
stress, to stimulate mast cells and lead to neurogenic
inflammation [31]. The possible release of NT under
stress may be relevant to the finding of higher inci-
dence of prenatal stressors in mothers of children with
ASD [32]. The present study did not attempt to corre-
late serum NT to levels of stress. Future studies could
employ the Hamilton Anxiety Scale or the Spielber-
ger’s State-Trait-Anxiety Inventory, as well as measure
serum levels of cortisol, adrenocorticotropic hormone
(ACTH) and CRH. It is interesting that mast cells can
degrade NT [33,34]. This action suggests that mast
cells have developed a rapid mechanism for limiting
stimulation by NT that implies an important patho-
physiological role.
Mast cells are involved in both innate and acquired
immunity [35], as well as in inflammation [13]. More-
over, mast cells can release some mediators “selectively”,
without concomitant secretion of either one of their
“flagship” molecules histamine or tryptase [36], making
serum measurement of these mediators as biomarkers
irrelevant. Moreover, histamine is metabolized rapidly,
while tryptase is elevated only in anaphylaxis and masto-
cytosis, conditions that were part of the exclusion cri-
teria. It is not apparent at present which mast cell
mediators are secreted in response to NT. Our prelimin-
ary findings on Luminex measurements of IL-4, IL-5,
IL-6, IL-8, IL-13 and tumor necrosis factor (TNF) did
not show any significant difference (results not shown).
Even though IL-6 expression was elevated in the brains
of deceased ASD patients [37], and it was detected at
low levels in the CSF in subjects with autism (n = 12), it
was not significantly elevated in the serum of autistic
subjects (n = 35) compared to control subjects with
other neurologic disorders (n = 21) [38]. Elsewhere,
there was only a trend towards increased production of
IL-6 and TNF-a in whole blood of autistic children as
compared to normal controls [39]. Another study
reported that TNF-a levels in CSF of patients with ASD
(n = 10) were significantly higher than concurrent
serum levels [40]. TNF is uniquely stored in mast cell
granules [41], and brain mast cells were reported to
secrete TNF [42]. It may well be that NT levels are suf-
ficient to activate only brain and gut mast cells, thus not
significantly raising systemic levels. Alternatively, mast
cells may release additional mediators that have not
been identified so far.
The present results indicate that NT is increased in
young children with autistic disorder and could partici-
pate in altered innate immunity and brain inflammation.
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